

TDMS No. 20107 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

N,N-Dimethyl-p-toluidine

CAS Number: 99-97-8

Date Report Requested: 03/10/2011

Time Report Requested: 11:42:39

First Dose M/F: 10/26/04 / 10/25/04

Lab: BAT

F1_M3

C Number: C20107
Lock Date: 02/26/2008
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.3.0
PWG Approval Date: NONE

TDMS No. 20107 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

N,N-Dimethyl-p-toluidine

CAS Number: 99-97-8

Date Report Requested: 03/10/2011

Time Report Requested: 11:42:39

First Dose M/F: 10/26/04 / 10/25/04

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
------------------	---------	---------	----------	----------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Dosing Accident	2			
Moribund Sacrifice	5	4	11	14
Natural Death	9	10	8	
Survivors				
Natural Death	1			
Terminal Sacrifice	33	36	31	36
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Necrosis	1 (2%)			
Perforation	1 (2%)			
Periesophageal Tissue, Inflammation	2 (4%)			
Gallbladder	(49)	(50)	(47)	(49)
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Intestine Large, Colon	(50)	(50)	(50)	(50)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Peyer's Patch, Hyperplasia		1 (2%)		
Liver	(50)	(50)	(50)	(50)
Angiectasis	3 (6%)	1 (2%)		
Basophilic Focus	5 (10%)	11 (22%)	8 (16%)	2 (4%)
Clear Cell Focus	15 (30%)	22 (44%)	15 (30%)	7 (14%)
Eosinophilic Focus	25 (50%)	30 (60%)	39 (78%)	43 (86%)
Fatty Change		3 (6%)	1 (2%)	2 (4%)
Hematopoietic Cell Proliferation	4 (8%)	1 (2%)	4 (8%)	1 (2%)
Inflammation, Chronic Active	23 (46%)	22 (44%)	18 (36%)	19 (38%)
Mineralization		1 (2%)	1 (2%)	1 (2%)
Mitotic Alteration	1 (2%)	1 (2%)	2 (4%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20107 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 N,N-Dimethyl-p-toluidine
 CAS Number: 99-97-8

Date Report Requested: 03/10/2011
 Time Report Requested: 11:42:39
 First Dose M/F: 10/26/04 / 10/25/04
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
Mixed Cell Focus	21 (42%)	25 (50%)	17 (34%)	12 (24%)
Necrosis	9 (18%)	8 (16%)	7 (14%)	10 (20%)
Pigmentation		3 (6%)	2 (4%)	2 (4%)
Bile Duct, Cyst		1 (2%)	1 (2%)	
Bile Duct, Hyperplasia	1 (2%)	1 (2%)	2 (4%)	
Centrilobular, Degeneration	1 (2%)		1 (2%)	
Hepatocyte, Hypertrophy	1 (2%)	9 (18%)	11 (22%)	16 (32%)
Hepatocyte, Karyomegaly	1 (2%)			
Kupffer Cell, Hyperplasia				1 (2%)
Oval Cell, Hyperplasia	1 (2%)		1 (2%)	2 (4%)
Mesentery	(4)	(3)	(5)	(2)
Inflammation, Suppurative	1 (25%)			
Fat, Necrosis	2 (50%)	3 (100%)	5 (100%)	2 (100%)
Vein, Thrombosis	1 (25%)			
Pancreas	(50)	(50)	(50)	(50)
Atrophy		1 (2%)	1 (2%)	1 (2%)
Basophilic Focus			1 (2%)	
Inflammation			1 (2%)	
Acinus, Hyperplasia				1 (2%)
Duct, Cyst			1 (2%)	2 (4%)
Salivary Glands	(50)	(50)	(50)	(50)
Fibrosis	1 (2%)			
Stomach, Forestomach	(50)	(50)	(50)	(50)
Erosion	2 (4%)	1 (2%)		
Hemorrhage				1 (2%)
Inflammation	13 (26%)	12 (24%)	13 (26%)	8 (16%)
Necrosis				1 (2%)
Ulcer	5 (10%)	4 (8%)	5 (10%)	5 (10%)
Epithelium, Hyperplasia	14 (28%)	14 (28%)	17 (34%)	11 (22%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Inflammation		1 (2%)	1 (2%)	
Mineralization			1 (2%)	
Epithelium, Necrosis	1 (2%)	1 (2%)	1 (2%)	
Tongue	(2)	(0)	(0)	(0)
Angiectasis	1 (50%)			
Cyst	1 (50%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20107 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

N,N-Dimethyl-p-toluidine

CAS Number: 99-97-8

Date Report Requested: 03/10/2011

Time Report Requested: 11:42:39

First Dose M/F: 10/26/04 / 10/25/04

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
Tooth Dysplasia	(37) 34 (92%)	(38) 36 (95%)	(34) 34 (100%)	(30) 26 (87%)
CARDIOVASCULAR SYSTEM				
Blood Vessel Inflammation	(50)	(50)	(50) 1 (2%)	(50)
Mineralization				1 (2%)
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	8 (16%)	7 (14%)	10 (20%)	13 (26%)
Inflammation	2 (4%)			1 (2%)
Mineralization		1 (2%)	2 (4%)	5 (10%)
Atrium, Thrombosis		1 (2%)		
Valve, Thrombosis	1 (2%)			
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Hypertrophy	3 (6%)	3 (6%)	1 (2%)	1 (2%)
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	1 (2%)			1 (2%)
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	12 (24%)	5 (10%)	2 (4%)	1 (2%)
Parathyroid Gland	(40)	(43)	(45)	(42)
Amyloid Deposition			1 (2%)	
Pituitary Gland	(50)	(50)	(49)	(50)
Pars Distalis, Hyperplasia	1 (2%)	1 (2%)		
Thyroid Gland	(50)	(50)	(50)	(50)
GENERAL BODY SYSTEM				
None				

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20107 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

N,N-Dimethyl-p-toluidine

CAS Number: 99-97-8

Date Report Requested: 03/10/2011

Time Report Requested: 11:42:39

First Dose M/F: 10/26/04 / 10/25/04

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
GENITAL SYSTEM				
Coagulating Gland	(0)	(1)	(0)	(0)
Inflammation		1 (100%)		
Epididymis	(50)	(50)	(50)	(50)
Angiectasis				1 (2%)
Granuloma Sperm		2 (4%)		
Inflammation				1 (2%)
Preputial Gland	(50)	(50)	(50)	(50)
Atrophy	1 (2%)			
Ectasia	7 (14%)	6 (12%)	7 (14%)	8 (16%)
Inflammation		1 (2%)	1 (2%)	1 (2%)
Prostate	(50)	(50)	(50)	(50)
Inflammation	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Epithelium, Hyperplasia	1 (2%)			
Seminal Vesicle	(50)	(50)	(50)	(50)
Inflammation	1 (2%)	1 (2%)		
Mineralization	1 (2%)			
Testes	(50)	(50)	(50)	(50)
Hyperplasia, Oncocytic		1 (2%)		
Germinal Epithelium, Degeneration		2 (4%)	3 (6%)	
Germinal Epithelium, Mineralization			1 (2%)	
Interstitial Cell, Hyperplasia	1 (2%)			1 (2%)

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)
Atrophy	3 (6%)		1 (2%)	
Hyperplasia	8 (16%)	6 (12%)	9 (18%)	9 (18%)
Necrosis			1 (2%)	
Thrombosis		1 (2%)		
Lymph Node	(2)	(3)	(4)	(0)
Lymph Node, Mandibular	(50)	(50)	(49)	(50)
Atrophy	5 (10%)	4 (8%)	6 (12%)	3 (6%)
Hyperplasia, Lymphoid	2 (4%)	1 (2%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20107 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

N,N-Dimethyl-p-toluidine

CAS Number: 99-97-8

Date Report Requested: 03/10/2011

Time Report Requested: 11:42:39

First Dose M/F: 10/26/04 / 10/25/04

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
Necrosis	1 (2%)			
Lymph Node, Mesenteric	(50)	(50)	(49)	(50)
Atrophy	13 (26%)	9 (18%)	14 (29%)	15 (30%)
Hyperplasia, Lymphoid				2 (4%)
Spleen	(48)	(50)	(49)	(50)
Atrophy	4 (8%)	11 (22%)	11 (22%)	6 (12%)
Hematopoietic Cell Proliferation	15 (31%)	18 (36%)	23 (47%)	22 (44%)
Hyperplasia, Lymphoid	5 (10%)	9 (18%)	6 (12%)	9 (18%)
Necrosis, Lymphoid	1 (2%)			
Pigmentation	38 (79%)	34 (68%)	25 (51%)	44 (88%)
Red Pulp, Atrophy	4 (8%)	1 (2%)	2 (4%)	2 (4%)
Thymus	(48)	(48)	(48)	(49)
Atrophy	41 (85%)	47 (98%)	47 (98%)	48 (98%)
Hyperplasia, Lymphoid	1 (2%)			1 (2%)
Infiltration Cellular, Mast Cell				1 (2%)
Necrosis	2 (4%)			
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(50)	(50)
Inflammation	3 (6%)	1 (2%)	1 (2%)	1 (2%)
Ulcer	4 (8%)	1 (2%)	1 (2%)	2 (4%)
Dermis, Fibrosis	2 (4%)			1 (2%)
Epidermis, Hyperplasia	1 (2%)		1 (2%)	1 (2%)
Hair Follicle, Hyperkeratosis				1 (2%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Fibrosis	1 (2%)			
Fracture		1 (2%)		
Osteopetrosis		1 (2%)		
Skeletal Muscle	(0)	(1)	(2)	(2)
Inflammation				1 (50%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20107 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

N,N-Dimethyl-p-toluidine

CAS Number: 99-97-8

Date Report Requested: 03/10/2011

Time Report Requested: 11:42:39

First Dose M/F: 10/26/04 / 10/25/04

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
------------------	---------	---------	----------	----------

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(50)
Hemorrhage			1 (2%)	
Hydrocephalus			1 (2%)	1 (2%)
Necrosis			1 (2%)	
Olfactory Lobe, Atrophy		1 (2%)		5 (10%)

RESPIRATORY SYSTEM

Lung	(50)	(50)	(50)	(50)
Foreign Body	1 (2%)			
Hemorrhage				1 (2%)
Inflammation, Chronic Active				1 (2%)
Alveolar Epithelium, Hyperplasia	3 (6%)	8 (16%)	3 (6%)	
Alveolar Epithelium, Metaplasia	1 (2%)		1 (2%)	
Alveolus, Infiltration Cellular, Histiocyte	1 (2%)	2 (4%)	2 (4%)	10 (20%)
Artery, Inflammation		1 (2%)		
Bronchiole, Epithelium, Hyperplasia		1 (2%)		
Bronchiole, Epithelium, Regeneration			1 (2%)	1 (2%)
Bronchus, Necrosis			1 (2%)	
Bronchus, Epithelium, Regeneration				1 (2%)
Mediastinum, Inflammation	1 (2%)			
Perivascular, Infiltration Cellular, Lymphoid			1 (2%)	
Serosa, Inflammation	1 (2%)			
Nose	(49)	(50)	(50)	(50)
Foreign Body		1 (2%)		
Hyperplasia		1 (2%)		
Inflammation	13 (27%)	12 (24%)	10 (20%)	20 (40%)
Polyp, Inflammatory	3 (6%)	2 (4%)		
Glands, Olfactory Epithelium, Dilatation	4 (8%)	11 (22%)	7 (14%)	48 (96%)
Glands, Olfactory Epithelium, Hyperplasia	4 (8%)	9 (18%)	7 (14%)	49 (98%)
Glands, Olfactory Epithelium, Metaplasia, Respiratory	5 (10%)	5 (10%)	6 (12%)	48 (96%)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
Glands, Respiratory Epithelium, Dilatation	17 (35%)	19 (38%)	13 (26%)	41 (82%)
Glands, Respiratory Epithelium, Hyperplasia	4 (8%)	2 (4%)	2 (4%)	11 (22%)
Glands, Respiratory Epithelium, Metaplasia, Respiratory	2 (4%)	2 (4%)	2 (4%)	10 (20%)
Nasolacrimal Duct, Hyperplasia, Regenerative				4 (8%)
Nerve, Atrophy	2 (4%)	7 (14%)	4 (8%)	42 (84%)
Olfactory Epithelium, Accumulation, Hyaline Droplet	12 (24%)	14 (28%)	10 (20%)	4 (8%)
Olfactory Epithelium, Metaplasia, Respiratory	10 (20%)	10 (20%)	5 (10%)	49 (98%)
Olfactory Epithelium, Necrosis	1 (2%)	3 (6%)	3 (6%)	8 (16%)
Respiratory Epithelium, Accumulation, Hyaline Droplet	24 (49%)	25 (50%)	24 (48%)	25 (50%)
Respiratory Epithelium, Hyperplasia	37 (76%)	35 (70%)	32 (64%)	30 (60%)
Respiratory Epithelium, Necrosis		1 (2%)	1 (2%)	1 (2%)
Transitional Epithelium, Hyperplasia				1 (2%)
Transitional Epithelium, Necrosis				1 (2%)
Vomer nasal Organ, Necrosis		1 (2%)	2 (4%)	3 (6%)
Trachea	(50)	(50)	(50)	(50)
Necrosis				1 (2%)

SPECIAL SENSES SYSTEM

Ear	(1)	(0)	(0)	(0)
External Ear, Inflammation	1 (100%)			
External Ear, Necrosis	1 (100%)			
Eye	(50)	(50)	(50)	(50)
Cornea, Inflammation	3 (6%)	1 (2%)	4 (8%)	
Lens, Cataract			1 (2%)	
Optic Nerve, Atrophy		1 (2%)		
Harderian Gland	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	
Hyperplasia	1 (2%)	4 (8%)	1 (2%)	1 (2%)
Zymbal's Gland	(1)	(0)	(0)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20107 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

N,N-Dimethyl-p-toluidine

CAS Number: 99-97-8

Date Report Requested: 03/10/2011

Time Report Requested: 11:42:39

First Dose M/F: 10/26/04 / 10/25/04

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Accumulation, Hyaline Droplet	1 (2%)			
Infarct	3 (6%)	2 (4%)		2 (4%)
Inflammation	2 (4%)	1 (2%)		
Mineralization	5 (10%)	7 (14%)	9 (18%)	6 (12%)
Nephropathy	39 (78%)	41 (82%)	43 (86%)	37 (74%)
Pigmentation			2 (4%)	
Cortex, Cyst	3 (6%)	2 (4%)	1 (2%)	2 (4%)
Papilla, Necrosis	1 (2%)	1 (2%)		
Pelvis, Dilatation	2 (4%)		1 (2%)	1 (2%)
Renal Tubule, Dilatation				1 (2%)
Renal Tubule, Hyperplasia				1 (2%)
Renal Tubule, Necrosis			2 (4%)	1 (2%)
Ureter	(1)	(0)	(0)	(0)
Inflammation	1 (100%)			
Necrosis	1 (100%)			
Urethra	(0)	(1)	(0)	(0)
Inflammation		1 (100%)		
Necrosis		1 (100%)		
Urinary Bladder	(50)	(50)	(50)	(50)
Calculus Gross Observation				2 (4%)
Inflammation				1 (2%)
Transitional Epithelium, Hyperplasia				1 (2%)

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20107 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

N,N-Dimethyl-p-toluidine

CAS Number: 99-97-8

Date Report Requested: 03/10/2011

Time Report Requested: 11:42:39

First Dose M/F: 10/26/04 / 10/25/04

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
--------------------	---------	---------	----------	----------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Dosing Accident		1	1	2
Moribund Sacrifice	3	1	7	10
Natural Death	4	8	3	6
Survivors				
Terminal Sacrifice	43	40	39	32
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Foreign Body				1 (2%)
Perforation			1 (2%)	1 (2%)
Epithelium, Inflammation				1 (2%)
Muscularis, Degeneration			1 (2%)	1 (2%)
Muscularis, Inflammation	1 (2%)			
Periesophageal Tissue, Hemorrhage			1 (2%)	
Gallbladder	(50)	(50)	(49)	(49)
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Fibrosis		1 (2%)		
Lymphoid Tissue, Hyperplasia, Lymphoid	1 (2%)			
Intestine Large, Colon	(50)	(50)	(50)	(50)
Fibrosis		1 (2%)		
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Fibrosis		1 (2%)		
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Fibrosis		1 (2%)		
Peyer's Patch, Hyperplasia, Lymphoid		1 (2%)		
Liver	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)			
Basophilic Focus	7 (14%)	5 (10%)	9 (18%)	11 (22%)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
Clear Cell Focus		2 (4%)	2 (4%)	3 (6%)
Eosinophilic Focus	20 (40%)	18 (36%)	45 (90%)	38 (76%)
Fatty Change	1 (2%)			8 (16%)
Hematopoietic Cell Proliferation	2 (4%)	4 (8%)	2 (4%)	3 (6%)
Inflammation, Chronic Active	39 (78%)	27 (54%)	33 (66%)	35 (70%)
Mineralization				1 (2%)
Mixed Cell Focus	3 (6%)	9 (18%)	7 (14%)	7 (14%)
Necrosis	1 (2%)	8 (16%)	4 (8%)	10 (20%)
Pigmentation	1 (2%)	1 (2%)	1 (2%)	4 (8%)
Bile Duct, Cyst	2 (4%)	1 (2%)	1 (2%)	3 (6%)
Hepatocyte, Hypertrophy		11 (22%)	10 (20%)	17 (34%)
Kupffer Cell, Hyperplasia		1 (2%)		1 (2%)
Oval Cell, Hyperplasia				2 (4%)
Serosa, Fibrosis		1 (2%)		
Serosa, Inflammation, Chronic Active		1 (2%)		
Mesentery	(3)	(8)	(9)	(6)
Inflammation, Chronic		1 (13%)		
Fat, Necrosis	3 (100%)	5 (63%)	9 (100%)	6 (100%)
Pancreas	(50)	(50)	(50)	(50)
Atrophy	1 (2%)		2 (4%)	
Acinus, Hyperplasia				1 (2%)
Acinus, Necrosis				1 (2%)
Duct, Cyst			2 (4%)	
Salivary Glands	(50)	(50)	(50)	(48)
Atrophy				1 (2%)
Fibrosis				1 (2%)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Erosion		1 (2%)		2 (4%)
Fibrosis		1 (2%)		
Inflammation	3 (6%)	4 (8%)	7 (14%)	16 (32%)
Necrosis	1 (2%)			
Ulcer	2 (4%)	2 (4%)	4 (8%)	7 (14%)
Epithelium, Cyst		1 (2%)		1 (2%)
Epithelium, Hyperplasia	3 (6%)	5 (10%)	12 (24%)	17 (34%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Mineralization	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20107 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

N,N-Dimethyl-p-toluidine

CAS Number: 99-97-8

Date Report Requested: 03/10/2011

Time Report Requested: 11:42:39

First Dose M/F: 10/26/04 / 10/25/04

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
Epithelium, Necrosis Glands, Dysplasia	1 (2%)			1 (2%)
Tongue	(0)	(0)	(0)	(1)
Cyst				1 (100%)
Tooth	(13)	(10)	(7)	(4)
Dysplasia	13 (100%)	10 (100%)	4 (57%)	4 (100%)
Peridental Tissue, Pulp, Inflammation	1 (8%)			
CARDIOVASCULAR SYSTEM				
Blood Vessel	(50)	(49)	(50)	(50)
Embolus Bacterial		1 (2%)		
Inflammation				3 (6%)
Media, Pulmonary Artery, Hyperplasia		1 (2%)		
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	5 (10%)	2 (4%)	4 (8%)	2 (4%)
Inflammation				1 (2%)
Mineralization	1 (2%)	2 (4%)	1 (2%)	5 (10%)
Necrosis			2 (4%)	
Epicardium, Fibrosis				1 (2%)
Valve, Thrombosis		1 (2%)	1 (2%)	
Ventricle, Thrombosis			1 (2%)	
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Angiectasis		1 (2%)		
Necrosis			2 (4%)	
Vacuolization Cytoplasmic			1 (2%)	
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	3 (6%)			
Necrosis			1 (2%)	
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia		1 (2%)		2 (4%)
Parathyroid Gland	(48)	(38)	(38)	(34)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20107 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

N,N-Dimethyl-p-toluidine

CAS Number: 99-97-8

Date Report Requested: 03/10/2011

Time Report Requested: 11:42:39

First Dose M/F: 10/26/04 / 10/25/04

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
Pituitary Gland	(48)	(50)	(50)	(49)
Pars Distalis, Angiectasis				1 (2%)
Pars Distalis, Hyperplasia	5 (10%)	3 (6%)	3 (6%)	3 (6%)
Pars Intermedia, Hyperplasia	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Thyroid Gland	(50)	(50)	(50)	(50)
Atrophy		2 (4%)		
Inflammation		1 (2%)	1 (2%)	
Follicle, Degeneration			1 (2%)	
Follicular Cell, Hyperplasia		1 (2%)		
Follicular Cell, Hypertrophy			1 (2%)	
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Clitoral Gland	(50)	(50)	(50)	(49)
Ovary	(50)	(49)	(50)	(50)
Angiectasis	2 (4%)		1 (2%)	1 (2%)
Atrophy	40 (80%)	43 (88%)	40 (80%)	45 (90%)
Cyst	4 (8%)	6 (12%)	4 (8%)	2 (4%)
Hemorrhage	2 (4%)		1 (2%)	
Inflammation		2 (4%)		
Thrombosis	2 (4%)			3 (6%)
Oviduct	(0)	(1)	(0)	(0)
Uterus	(50)	(50)	(50)	(50)
Angiectasis	2 (4%)	2 (4%)	1 (2%)	
Atrophy				1 (2%)
Dilatation	13 (26%)	13 (26%)	6 (12%)	10 (20%)
Inflammation	1 (2%)	3 (6%)	2 (4%)	
Thrombosis		1 (2%)	1 (2%)	
Endometrium, Hyperplasia, Cystic	25 (50%)	17 (34%)	11 (22%)	9 (18%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20107 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

N,N-Dimethyl-p-toluidine

CAS Number: 99-97-8

Date Report Requested: 03/10/2011

Time Report Requested: 11:42:39

First Dose M/F: 10/26/04 / 10/25/04

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(49)
Atrophy	1 (2%)	2 (4%)	2 (4%)	3 (6%)
Hyperplasia	5 (10%)	14 (28%)	15 (30%)	14 (29%)
Lymph Node	(7)	(3)	(5)	(4)
Lumbar, Hemorrhage				1 (25%)
Mediastinal, Hyperplasia, Lymphoid			1 (20%)	
Renal, Ectasia	2 (29%)			
Renal, Hemorrhage		1 (33%)		
Lymph Node, Mandibular	(50)	(50)	(50)	(48)
Atrophy	1 (2%)	4 (8%)	5 (10%)	5 (10%)
Hyperplasia, Lymphoid	3 (6%)	5 (10%)		3 (6%)
Hyperplasia, Plasma Cell		1 (2%)		
Lymph Node, Mesenteric	(49)	(49)	(49)	(50)
Angiectasis	1 (2%)			
Atrophy	1 (2%)	5 (10%)	5 (10%)	12 (24%)
Hyperplasia, Lymphoid	7 (14%)	3 (6%)	1 (2%)	
Infiltration Cellular, Plasma Cell			1 (2%)	
Inflammation, Granulomatous				1 (2%)
Necrosis				1 (2%)
Spleen	(49)	(49)	(49)	(50)
Atrophy	3 (6%)	8 (16%)	1 (2%)	6 (12%)
Hematopoietic Cell Proliferation	18 (37%)	23 (47%)	24 (49%)	21 (42%)
Hyperplasia, Lymphoid	14 (29%)	15 (31%)	12 (24%)	15 (30%)
Infarct		1 (2%)		
Infiltration Cellular, Plasma Cell	1 (2%)			
Pigmentation	37 (76%)	39 (80%)	33 (67%)	43 (86%)
Capsule, Fibrosis		1 (2%)		
Red Pulp, Atrophy				5 (10%)
Thymus	(50)	(50)	(48)	(48)
Atrophy	46 (92%)	46 (92%)	39 (81%)	43 (90%)
Hyperplasia, Histiocytic		1 (2%)		
Hyperplasia, Lymphoid	3 (6%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20107 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

N,N-Dimethyl-p-toluidine

CAS Number: 99-97-8

Date Report Requested: 03/10/2011

Time Report Requested: 11:42:39

First Dose M/F: 10/26/04 / 10/25/04

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
--------------------	---------	---------	----------	----------

INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(50)	(50)	(50)
Skin	(50)	(50)	(50)	(50)
Hemorrhage			1 (2%)	
Inflammation	1 (2%)	2 (4%)		1 (2%)
Ulcer		2 (4%)	2 (4%)	1 (2%)
Dermis, Fibrosis		1 (2%)	1 (2%)	
Epidermis, Hyperplasia	1 (2%)		2 (4%)	
Sebaceous Gland, Hyperplasia			1 (2%)	

MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(50)
Fibro-Osseous Lesion	3 (6%)	5 (10%)	6 (12%)	11 (22%)
Fracture				1 (2%)
Osteopetrosis	1 (2%)	1 (2%)		1 (2%)
Skeletal Muscle	(0)	(2)	(1)	(2)
Inflammation		1 (50%)		

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(49)
Necrosis	1 (2%)		1 (2%)	
Olfactory Lobe, Atrophy				8 (16%)
Peripheral Nerve	(0)	(0)	(1)	(0)
Spinal Cord	(0)	(0)	(1)	(0)

RESPIRATORY SYSTEM

Lung	(50)	(50)	(50)	(50)
Foreign Body		1 (2%)		2 (4%)
Hemorrhage			1 (2%)	
Inflammation		2 (4%)		2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
Alveolar Epithelium, Hyperplasia	2 (4%)	3 (6%)	8 (16%)	2 (4%)
Alveolus, Infiltration Cellular, Histiocyte	1 (2%)			7 (14%)
Bronchiole, Epithelium, Necrosis				1 (2%)
Bronchiole, Epithelium, Regeneration				5 (10%)
Bronchus, Necrosis				5 (10%)
Bronchus, Epithelium, Regeneration				5 (10%)
Nose	(50)	(49)	(50)	(50)
Inflammation	3 (6%)	7 (14%)	3 (6%)	32 (64%)
Glands, Lateral Wall, Dilatation				2 (4%)
Glands, Olfactory Epithelium, Dilatation	13 (26%)	14 (29%)	20 (40%)	46 (92%)
Glands, Olfactory Epithelium, Hyperplasia	2 (4%)	14 (29%)	14 (28%)	50 (100%)
Glands, Olfactory Epithelium, Metaplasia, Respiratory	2 (4%)	5 (10%)	7 (14%)	44 (88%)
Glands, Respiratory Epithelium, Dilatation	10 (20%)	17 (35%)	15 (30%)	33 (66%)
Glands, Respiratory Epithelium, Hyperplasia		2 (4%)	12 (24%)	13 (26%)
Glands, Respiratory Epithelium, Metaplasia, Respiratory			10 (20%)	10 (20%)
Nasolacrimal Duct, Hyperplasia, Regenerative				4 (8%)
Nerve, Atrophy				41 (82%)
Olfactory Epithelium, Accumulation, Hyaline Droplet	2 (4%)	5 (10%)	8 (16%)	15 (30%)
Olfactory Epithelium, Degeneration				1 (2%)
Olfactory Epithelium, Metaplasia, Respiratory	1 (2%)	6 (12%)	14 (28%)	46 (92%)
Olfactory Epithelium, Necrosis			3 (6%)	6 (12%)
Respiratory Epithelium, Accumulation, Hyaline Droplet	33 (66%)	34 (69%)	39 (78%)	36 (72%)
Respiratory Epithelium, Hyperplasia	11 (22%)	15 (31%)	11 (22%)	30 (60%)
Respiratory Epithelium, Hyperplasia, Regenerative				3 (6%)
Respiratory Epithelium, Necrosis				5 (10%)
Transitional Epithelium, Hyperplasia, Regenerative				1 (2%)
Transitional Epithelium, Necrosis				2 (4%)
Vomeranasal Organ, Necrosis				4 (8%)
Trachea	(50)	(50)	(50)	(50)
Inflammation				1 (2%)
Glands, Hyperplasia				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20107 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

N,N-Dimethyl-p-toluidine

CAS Number: 99-97-8

Date Report Requested: 03/10/2011

Time Report Requested: 11:42:39

First Dose M/F: 10/26/04 / 10/25/04

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG
--------------------	---------	---------	----------	----------

SPECIAL SENSES SYSTEM

Eye	(50)	(50)	(50)	(49)
Fibrosis			1 (2%)	
Cornea, Inflammation		1 (2%)	1 (2%)	3 (6%)
Lens, Cataract			1 (2%)	
Optic Nerve, Atrophy			1 (2%)	
Harderian Gland	(50)	(50)	(50)	(49)
Fibrosis		1 (2%)		
Hyperplasia	4 (8%)	2 (4%)		2 (4%)
Inflammation	1 (2%)			

URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)
Accumulation, Hyaline Droplet		2 (4%)	1 (2%)	
Infarct	4 (8%)	3 (6%)	4 (8%)	
Inflammation			1 (2%)	2 (4%)
Mineralization		1 (2%)		3 (6%)
Nephropathy	13 (26%)	15 (30%)	15 (30%)	17 (34%)
Cortex, Cyst				1 (2%)
Papilla, Necrosis				1 (2%)
Renal Tubule, Necrosis	1 (2%)		2 (4%)	2 (4%)
Urinary Bladder	(50)	(50)	(50)	(50)

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion